Zealand Pharma A/S
CSE:ZEAL

Watchlist Manager
Zealand Pharma A/S Logo
Zealand Pharma A/S
CSE:ZEAL
Watchlist
Price: 720 DKK -1.1% Market Closed
Market Cap: 50.9B DKK
Have any thoughts about
Zealand Pharma A/S?
Write Note

P/S
Price to Sales

661.7
Current
94.6
Median
7.6
Industry
Higher than median
Higher than industry value

Price to Sales (P/S) ratio is a valuation multiple that compares a company’s market capitalization to its revenues. It is an indicator of the value that financial markets have placed on each dollar of a company’s sales.

P/S
661.7
=
Market Cap
50.9B DKK
/
Revenue
76.9m DKK
All Countries
Close
Revenue Growth P/S to Growth
DK
Zealand Pharma A/S
CSE:ZEAL
Average P/S: 3 467 760.3
661.7
497%
1.3
FR
Pharnext SCA
OTC:PNEXF
38 142 781.8
N/A N/A
US
Abbvie Inc
NYSE:ABBV
5.7
20%
0.3
US
Amgen Inc
NASDAQ:AMGN
4.4
26%
0.2
US
Gilead Sciences Inc
NASDAQ:GILD
4.1
10%
0.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.8
34%
0.3
US
E
Epizyme Inc
F:EPE
1 847
N/A N/A
AU
CSL Ltd
ASX:CSL
5.7
23%
0.3
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.7
23%
0.2
US
S
Seagen Inc
F:SGT
17.8
118%
0.2
NL
argenx SE
XBRU:ARGX
19.3
220%
0.1

P/S Forward Multiples

Forward P/S multiple is a version of the P/S ratio that uses forecasted revenue for the P/S calculation. 1-Year, 2-Years, and 3-Years forwards use revenue forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
P/S
304.9
2-Years Forward
P/S
68.7
3-Years Forward
P/S
24.9

See Also

Discover More